WASHINGTON, Nov 13- A U.S. Supreme Court justice on Wednesday declined a request from Teva Pharmaceutical Industries for a stay of an appeals court ruling that would strip the company's $4 billion- a-year multiple sclerosis drug Copaxone of patent protection in 2014, rather than in 2015..
The U.S. Court of Appeals for the Federal Circuit issued its decision in a patent fight that pits Teva against two teams developing cheaper generic forms of Copaxone: one with Novartis AG and Momenta Pharmaceuticals Inc and another between Mylan Inc and Natco Pharma Ltd. Novartis did not immediately comment on the ruling.
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.
TheStreet.com offers up 13 biotech predictions for 2013.
Take a look at some of Monday's midday movers:
Take a look at some of Monday morning's early movers:
When someone calls about a stock Cramer doesn't know, he does his homework and follows up.
The Lightning Round is extended in this CNBC.com exclusive feature.
So far this year, the Russell 2000 index of small-cap companies continues to outperform the Dow, and the S&P 500. While most of these companies average only a $1 billion dollar market capitalization, some of their returns are proving resilient to an economic slowdown.
Rising oil prices have not stopped consumers from going to the mall. Retailer Guess is enjoying a 15% surge in their stock price. The clothing company reported better than expected revenue.